Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
As an ObGyn dedicated to helping patients achieve their weight loss goals, I often hear concerns about the side effects of GLP-1 medications, particularly nausea
The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Eating smaller, slower meals helps
From reformulation to portion control, appetite supression to satiety science - the GLP-1 revolution is reshaping how we think about food innovation and weight management
The primary endpoint is the time to the first occurrence of a composite primary outcome event, defined as a persistent eGFR decline (50% from baseline), reaching ESRD, renal death, or CV death
US$ 22.79
US$ 26.20
US$ 29.13
US$ 25.93
US$ 27.79
US$ 28.00
US$ 24.88
US$ 29.65
